Yesterday, we reported our Fiscal 2026 results. More importantly, they validate years of disciplined execution and the transformation of Tilray Brands. The @Tilray Brands of today is not the Tilray Brands of yesterday. Today, Tilray Brands is a global consumer products and pharmaceutical distribution company with leading positions across cannabis, beverage, hospitality and wellness. We are no longer defined by one category, one market or one regulatory outcome. We have built multiple scaled businesses that generate revenue, produce cash flow and create long-term shareholder value. Fiscal 2026 proved our strategy is working. We delivered record annual revenue of $915.5 million, record gross profit and record adjusted EBITDA of $61.1 million. We strengthened our balance sheet with approximately $235 million in cash, restricted cash and marketable securities while reducing net debt to just $0.7 million. On a pro forma basis, Tilray is now an approximately $1.2 billion annualized global revenue company. Today, Tilray operates one of the world’s largest cannabis cultivation platforms, with more than 6 million square feet of cultivation capacity across Canada and Europe. Combined with our pharmaceutical distribution, clinical care and medical cannabis infrastructure, we have built a global platform that is difficult to replicate. Europe has become one of Tilray’s strongest growth platforms. Our International Medical Cannabis business grew 34% in Fiscal 2026 as we expanded cultivation, pharmaceutical distribution, clinical care and patient access across the continent. We believe this remains one of our most exciting long-term growth opportunities. In Fiscal 2026, we also built a global beverage and hospitality platform approaching $500 million in annual revenue, strengthened by BrewDog and one of the industry’s most differentiated hospitality networks. Our pubs are more than hospitality assets, they are consumer engagement platforms that build brands, deepen consumer loyalty, generate valuable consumer insights and create experiences few beverage companies can replicate. Across the company, AI and data-driven technologies are helping us cultivate smarter, optimize operations, strengthen our supply chain, improve manufacturing and enable faster, better decision-making. Every acquisition, every investment and every operating decision has been guided by one objective: building a stronger company capable of creating long-term shareholder value. Today, those investments are translating into greater scale, stronger financial performance and a healthier balance sheet. As we enter Fiscal 2027, our priorities remain clear: allocate capital with discipline, improve operating efficiency, generate profitable growth and cash flow, and continue creating long-term shareholder value. None of this would be possible without the dedication of our employees around the world, the trust of our customers and partners, and the continued support of our shareholders. Thank you for believing in our vision. We’ve transformed the business. Now we’re focused on unlocking its full value. I believe Tilray’s best years are still ahead. ir.tilray.com/news-releases/… $TLRY

The World Cup has a unique way of bringing people together. This summer, @BrewDog Waterloo, the UK’s biggest bar, will welcome football fans from around the world for an unforgettable watch party experience. At @Tilray Brands, Inc., we believe great brands create meaningful connections. Whether it’s through our craft beverages, wellness products, or experiences like this, our goal is simple: bring people together around the moments that matter most. Proud of the BrewDog team for creating what promises to be one of the UK’s premier destinations to watch the World Cup this summer. And this is only the beginning. Stay tuned as we unveil additional fan experiences and activations across the U.S. and throughout our craft beverage portfolio in the weeks ahead. #WorldCupWatchParty #BrewDog #TilrayBrands

Today is a historic moment for the United States. With President Donald Trump officially rescheduling cannabis, federal policy is taking a meaningful step forward—aligning more closely with science, patient needs, and the reality millions of Americans live every day. At the heart of this decision are patients. Cancer patients seeking relief from chemotherapy. Seniors managing chronic pain. Veterans navigating PTSD. For decades, they have looked to medical cannabis as part of their care, and today marks real progress in expanding access and advancing the system that supports them. This is a major step forward for medical cannabis. Rescheduling unlocks the potential for accelerated clinical research, greater consistency and quality, and broader access to safe, regulated treatments, helping further establish cannabis as a credible therapeutic option within modern healthcare. At $TLRY, we’ve built our global platform for this moment. We operate at pharmaceutical-grade standards across more than 20 countries, serving hundreds of thousands of patients with high-quality medical cannabis products. Our experience in highly regulated markets positions us to help lead responsibly as the U.S. enters this next phase. What’s most exciting is what comes next - deepening the integration of medical cannabis into healthcare, advancing research, and ensuring patients have access to safe, standardized treatments. This is a defining milestone and a powerful step forward for patients and the future of healthcare.